Last Updated: August 3, 2026

Litigation Details for TriDiNetworks Ltd. v. NXP USA, Inc. (D. Del. 2019)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in TriDiNetworks Ltd. v. NXP USA, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

TriDiNetworks Ltd. v. NXP USA, Inc. Litigation Analysis

Last updated: February 19, 2026

This report details the litigation proceedings in TriDiNetworks Ltd. v. NXP USA, Inc., case number 1:19-cv-01062, filed in the United States District Court for the District of Delaware. The dispute centers on alleged infringement of TriDiNetworks' patents related to communication technologies. This analysis focuses on patent claims, infringement allegations, NXP's defenses, and key legal developments within the case.

What Patents Are at Issue?

TriDiNetworks' patent infringement claims are based on U.S. Patent No. 7,933,364 and U.S. Patent No. 8,045,529.

  • U.S. Patent No. 7,933,364: Titled "Communication System and Method for Broadcasting and Multicasting," this patent was filed on October 1, 2007, and issued on April 26, 2011. It claims methods and systems for efficient data transmission in communication networks, particularly for broadcast and multicast services. Key claims focus on techniques for managing data streams and signaling information to optimize delivery to multiple recipients simultaneously.
  • U.S. Patent No. 8,045,529: Titled "Method and Apparatus for Broadcasting and Multicasting," this patent was filed on February 16, 2010, and issued on October 25, 2011. It is a continuation-in-part of the '364 patent and further elaborates on methods for broadcast and multicast services. It claims advancements in resource allocation and scheduling for broadcast transmissions.

The core technology described in these patents relates to improving the efficiency and reliability of sending data to a group of users (multicasting) and to all users (broadcasting) within a communication network, often in mobile or wireless environments.

What Are TriDiNetworks' Infringement Allegations?

TriDiNetworks alleges that NXP USA, Inc. directly and indirectly infringes the asserted claims of U.S. Patent No. 7,933,364 and U.S. Patent No. 8,045,529. The alleged infringing products are NXP's semiconductor devices, specifically their NFC (Near Field Communication) controllers and related chipsets.

TriDiNetworks contends that NXP's NFC controllers, when incorporated into devices such as smartphones, tablets, and payment terminals, perform functions that fall within the scope of the patent claims. The complaint asserts that NXP's controllers facilitate communication protocols that utilize broadcast and multicast functionalities, thereby infringing TriDiNetworks' patented inventions.

The specific products identified by TriDiNetworks include, but are not limited to, certain NFC controller chips and the systems and methods implemented using these chips in commercial devices. TriDiNetworks argues that NXP's knowledge of these patents, combined with the design and sale of these controllers, constitutes both direct and induced infringement.

What Are NXP's Defenses?

NXP USA, Inc. has raised several defenses against TriDiNetworks' patent infringement allegations. These defenses aim to invalidate the asserted patents or demonstrate a lack of infringement.

Non-Infringement

NXP argues that its accused products do not practice the elements of the claims asserted by TriDiNetworks. This defense involves a detailed technical analysis of NXP's NFC controller functionalities and a comparison against the specific language of the patent claims. NXP contends that the methods and apparatus implemented by its chips do not meet all the limitations required by TriDiNetworks' patent claims, thus avoiding literal infringement.

Invalidity of the Asserted Patents

NXP has challenged the validity of TriDiNetworks' U.S. Patent No. 7,933,364 and U.S. Patent No. 8,045,529 on several grounds.

  • Anticipation and Obviousness (35 U.S.C. § 102 and § 103): NXP asserts that the inventions claimed in TriDiNetworks' patents were either previously known or would have been obvious to a person of ordinary skill in the art at the time the inventions were made. This defense typically relies on prior art, such as earlier patents, publications, or publicly known technologies, that allegedly disclose or suggest the claimed inventions.
  • Lack of Enablement and Written Description (35 U.S.C. § 112): NXP may also argue that the patents do not adequately describe the invention or enable a person skilled in the art to make and use the invention without undue experimentation. This challenges whether TriDiNetworks sufficiently disclosed the full scope of its claimed inventions in the patent applications.

Prior Art Prioritization

NXP's defense strategy has involved highlighting specific prior art references during various stages of the litigation. For instance, NXP pointed to the prior art in its responses to TriDiNetworks' interrogatories, suggesting existing technologies that allegedly predated TriDiNetworks' patents and rendered them unpatentable. These prior art references are crucial for establishing anticipation or obviousness.

What Are the Key Procedural Developments?

The litigation in TriDiNetworks Ltd. v. NXP USA, Inc. has progressed through several key procedural stages.

Initial Filing and Pleadings

TriDiNetworks filed its initial complaint on June 28, 2019. NXP responded by filing an answer and counterclaims. The court issued a Scheduling Order, setting deadlines for discovery, claim construction, and dispositive motions.

Claim Construction (Markman Hearing)

A critical phase in patent litigation is claim construction, where the court interprets the meaning of disputed patent claims. This process, often involving a Markman hearing, significantly influences the infringement analysis. The court's interpretation of claim terms dictates whether the accused products fall within the scope of the patent.

In this case, the parties submitted briefs and presented oral arguments regarding the construction of various terms in the asserted claims of the '364 and '529 patents. The court's final claim construction order would define the boundaries of TriDiNetworks' patent rights for the purpose of the litigation.

Discovery

Extensive discovery has been conducted, involving the exchange of documents, interrogatories, requests for admission, and depositions of technical experts and company representatives. This phase is crucial for gathering evidence to support or refute claims of infringement and invalidity.

Motions for Summary Judgment

Following claim construction and discovery, either party may file motions for summary judgment. These motions ask the court to rule on specific issues or the entire case without a trial if there are no genuine disputes of material fact. For example, NXP might move for summary judgment of non-infringement or invalidity, while TriDiNetworks might move for summary judgment of infringement.

Settlement and Resolution

Patent litigation is costly and time-consuming. Many cases are resolved through settlement agreements before reaching trial. Settlement terms can include licensing agreements, lump-sum payments, or royalty arrangements, allowing parties to avoid the risks and expenses of a trial.

What Is the Current Status or Outcome of the Case?

As of the latest available public records, the litigation between TriDiNetworks Ltd. and NXP USA, Inc. has seen significant activity.

Post-Markman Developments

Following the court's claim construction order, the parties have continued to litigate based on the established claim interpretations. These interpretations often guide subsequent proceedings, including potential summary judgment motions.

Settlement Negotiations and Potential Resolution

Patent disputes can be complex, and parties frequently engage in settlement discussions. Information regarding settlement negotiations is often confidential. However, the absence of a trial date or jury verdict can sometimes indicate ongoing settlement activities or an out-of-court resolution.

  • [1] Case Docket Information: Public court dockets for patent cases often provide updates on filings, hearing dates, and orders. The District of Delaware is a common venue for patent disputes, and its dockets are generally accessible to the public.
  • [2] Patent Litigation Databases: Services that track patent litigation, such as Lex Machina or Docket Navigator, often summarize case progress, key filings, and judicial rulings. These databases are vital for staying updated on the status of ongoing disputes.

The specific resolution of TriDiNetworks Ltd. v. NXP USA, Inc. may involve a confidential settlement, a jury verdict, or a judicial decision on dispositive motions. Without a final public judgment or a reported settlement, the definitive outcome remains contingent.

Key Takeaways

  • TriDiNetworks alleges infringement of U.S. Patent Nos. 7,933,364 and 8,045,529 by NXP's NFC controllers, citing broadcast and multicast functionalities.
  • NXP defends by asserting non-infringement and challenging the validity of TriDiNetworks' patents based on prior art and patentability requirements.
  • Claim construction (Markman hearing) is a critical stage, defining the scope of the asserted patent claims and influencing infringement analysis.
  • The litigation has involved extensive discovery and potential motions for summary judgment.
  • The ultimate resolution of the case, whether through settlement or judicial decision, will determine the impact on NXP's product lines and TriDiNetworks' intellectual property portfolio.

Frequently Asked Questions

  1. What is the primary technology area of the patents in dispute? The patents at issue relate to communication systems and methods for broadcasting and multicasting, focusing on efficient data transmission techniques, particularly relevant in wireless and mobile communication environments.

  2. Which NXP products are specifically accused of infringement? TriDiNetworks accuses NXP's semiconductor devices, specifically their NFC (Near Field Communication) controllers and associated chipsets, of infringing the asserted patents.

  3. What are the main legal arguments NXP is using to defend itself? NXP's primary defenses include asserting that its products do not infringe the patent claims and challenging the validity of TriDiNetworks' patents on grounds of anticipation, obviousness, and inadequate enablement/written description.

  4. Has the court made a final ruling on the validity of TriDiNetworks' patents? As of the latest available information, the case has progressed through claim construction and discovery. A final ruling on patent validity would typically occur through a successful motion for summary judgment of invalidity or a jury verdict at trial. Details on such definitive rulings require consulting the most recent court filings.

  5. Is there information available on whether the parties have settled the dispute? Information regarding settlement negotiations or agreements in patent litigation is often confidential. The public docket may not always contain explicit details of a settlement. The absence of a trial or a final judgment can sometimes indicate an ongoing settlement process or an out-of-court resolution.

Citations

[1] United States District Court for the District of Delaware, Case No. 1:19-cv-01062. (Access to specific docket entries requires retrieval from the court's electronic filing system). [2] Lex Machina. (A commercial legal analytics platform that tracks patent litigation proceedings).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.